Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-08-29
2011-12-06
Bristol, Lynn (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S143100
Reexamination Certificate
active
08071321
ABSTRACT:
The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against a tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.
REFERENCES:
patent: 4737462 (1988-04-01), Mark et al.
patent: 4738845 (1988-04-01), Bell et al.
patent: 4753795 (1988-06-01), Bell et al.
patent: 4793995 (1988-12-01), Bell et al.
patent: 6514729 (2003-02-01), Bentzien
patent: 6710086 (2004-03-01), Lai et al.
patent: 2001/0042551 (2001-11-01), Kutzko et al.
patent: 2004/0022869 (2004-02-01), Chen et al.
patent: 2006/0228326 (2006-10-01), Fidler et al.
patent: 0 536 520 (1993-04-01), None
patent: 0 835 661 (1998-04-01), None
patent: WO 2004/037182 (2004-05-01), None
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).
Mocellin et al. (Biochem. Biophys. Acta 1653:61-71 (2003)).
American Cancer Society, Cancer reference information: “How is melanoma skin cancer staged?”, pp. 1-7 (May 14, 2009).
American Cancer Society, Cancer reference information: “How are brain and spinal tumors in adults staged?”, p. 1 (Aug. 28, 2009).
Bordignon et al (Haematologica 84:1110-1149 (1999)).
Leitner et al., “Type I Interferons are essential for the efficacy of replicase-based DNA vaccines”, Vaccine 24:24 , 5110-5118 (2006).
Zhang et al., “A novel DNA vaccine based on ubiquitin-proteasome pathway targeting ‘self’-antigens expressed in melanoma/melanocyte”, Gene Ther. 12:13, 1049-1057 (2005).
Shibata et al., “Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene”, J. Immunol. 177:6, 3564-3576 (2006).
Dezfouli et al., “Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells”, Immunol. Cell Biol. 81 :6, 459-471 (2003).
Sterman et al., “A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses”, Clin. Cancer Res. 13 :15, 4456-4466 (2007).
Kruklitis et al., “Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma”, J. Thorac. Cardiovasc. Surg. 127 :1, 123-130 (2004).
Saito et al., “Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma”, Int. J. Cancer 111: 5, 777-782 (2004).
Borden, “Augmentatio n of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma”, Cytokine. Growth Factor Rev. 18:5-6, 491-501 (2007).
Learman et al., “Novel growth and death related interferon-stimulated gene s (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2”, J. Interferon Cytokine. Res. 23: 12, 745-756 (2003).
Sarkar et al., “Defining the mechanism by which IFN-beta dowregulates c-myc expression in human melan oma cells: pivotal role of human polynucleotide phosphorylase (hPNPaseold-35)”, Cell Death Differ. 13 :9, 1541-1553 (2006).
Staudt et al., “Model cell culture system for defining the molecular and biochemical events mediating terminal differentiation of human melanoma cells”, J. Cell. Physiol. online (Oct. 9, 2008).
Gogas et al., “Prognostic significance of autoimmunity during treatment of melanoma with interferon”, N. Engl . J. Med. 354:7, 709-718 (2006).
Moschos et al., “Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma”, Cytokine. Growth Factor Rev. 18:5-6, 451-458 (2007).
Brown et al., “Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitutmor effects”, Surgery 140 :2, 297-306 (2006).
Kubo et al., “Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells”, Arch. Dermatol. Res. 300:6, 297-301 (2008).
Rapprich et al., “Intralesional therapy of metastatic spreading melanoma with beta-interferon”, J. Dtsch. Dermatol. Ges. 4 :9, 743-746 (2006).
Kawada et al., “Local injection of interferon beta in malignan t melanoma of the esophagus as adjuvant of systemic pre- and postoperative DAV chemotherapy: case report with 7 years of long-term survival”, Gastrointest. Endosc. 66 :2, 408-410 (2007).
Voelter-Mahlknecht et al., “Phase 2 trial of the continuou s IV administration of interferon-beta in patients with disseminated malignant melanoma”, Skinmed. 5:6, 271-276 (2006).
Gibbs et al., “Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon-beta”, Eur. J. Neurol. 15:1, e4-EOA (2008).
Streck et al., “Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta”, Cancer Gene Ther. 13:1, 99-106 (2006).
Gurguta et al., “Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C”, Am. J. Gastroenterol. 101:1, 197-198 (2006).
Kameyama et al., “Expression of melanocyte stimulating hormone receptors correlates with mammalian pigmentation, and ca n be modulated by interferons”, J. Cell. Physiol. 137:1, 35-44 (1988).
Zimmerer et al., “Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha”, Clin. Cancer Res. 14:18, 5900-5906 (2008).
Carretero et al., “Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy”, Immunogenetics 60:8, 439-447 (2008).
Domingo-Domenech et al., “Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon—comparison with tyrosinase rt-PCR”, Oncology 68:4-6, 341-349 (2005).
Terheyden et al., “Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression”, Scand . J. Immunol. 58 :5, 566-571 (2003).
Ryuke et al., “Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy”, Melanoma Res. 13:4, 349-356 (2003).
Odaka et al., “Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity”, Cancer Res. 61 :16, 6201-6212 (2001).
DeLong et al., “Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy”, Cancer Res. 63:22, 7845-7852 (2003).
Birlea et al., “Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigment ation”, Curr. Drug Targets 9:4, 345-359 (2008).
Fisher et al., “Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells”, J. Interferon Res. 5 :1, 11-22 (1985).
Fisher et al., “Interferon inhibits m elanogenesis in B-16 mouse melanoma cells”, Biochem. Biophys. Res. Commun. 100 :2, 823-830 (1981).
Takahashi et al., “Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumo r cells”, Cancer Sci. 99:8, 1650-1655 (2008).
Ekmekcioglu et al
Dunn Ian S.
Durda Paul
Kurnick James T.
Bristol Lynn
Clark & Elbing LLP
CytoCure LLC
LandOfFree
Methods for up-regulating antigen expression in tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for up-regulating antigen expression in tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for up-regulating antigen expression in tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314159